Tarsus Pharmaceuticals, Inc.

TARS Nasdaq SEC CIK 1819790
Follow Tarsus Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $194.6M +63.9% vs same quarter last year
Net income −$668.3M −5210.6% vs same quarter last year
EPS, diluted −$14.40 −4700% vs same quarter last year
Operating cash flow −$6M −132.9% vs same quarter last year
Revenue by quarter
$66.4M
$78.3M
$102.7M
$118.7M
$151.7M
$162.1M
$173.9M
$194.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$451.4M−$66M
FY24$183M−$116M
FY23$17.4M−$136M
FY22$25.8M−$62.1M
FY21$57M−$13.8M
FY20$0−$26.8M
FY19-−$4.7M
FY18-−$1.3M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1000%−750%−500%−250%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−15.7%−14.6%
FY24−65.9%−63.4%
FY23−820.5%−779.5%
FY22−242.9%−240.5%
FY21−21.3%−24.2%
FY20--
FY19--
FY18--
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$22.3M
FY24−$84.6M
FY23−$119M
FY22−$49.5M
FY21$3.2M
FY20−$21.6M
FY19−$3.8M
FY18-
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Tarsus Pharmaceuticals
  • Healthcare median
−800%−600%−400%−200%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearTarsus PharmaceuticalsHealthcare median
FY25−14.6%−30.6%
FY24−63.4%−47%
FY23−779.5%−58%
FY22−240.5%−80.4%
FY21−24.2%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%